Exact Sciences
Exact Sciences Corporation, headquartered in Madison, Wisconsin, specializes in cancer screening and diagnostic tests, both in the United States and internationally. The company is best known for Cologuard, a non-invasive stool-based DNA test designed to detect colorectal cancer and pre-cancer. Additionally, Exact Sciences offers Oncotype DX, a suite of gene expression tests that assess recurrence risk and chemotherapy benefits for breast, prostate, and colon cancers. The company is actively developing liquid biopsy tests aimed at improving cancer detection and monitoring, including tests for molecular residual disease and additional cancers. Exact Sciences holds exclusive intellectual property for its screening technology, which is recognized in the colorectal cancer screening guidelines of leading medical organizations.
Ashion Analytics is a clinical genomics testing company focused on enhancing the application of genomic data to support healthcare providers in delivering tailored treatment options for patients. The company operates a laboratory that addresses the complex needs of clinical, academic, and biopharma clients by offering a range of services, including large panel tests, whole exome sequencing, RNA sequencing, and support for research and drug development. Through its commitment to personalized medicine and data analytics, Ashion Analytics aims to improve patient outcomes by ensuring that healthcare providers have access to the necessary genomic information to make informed treatment decisions.
Viomics Inc. develops and delivers cancer detection technologies to enable early and targeted intervention that cures previously deadly cancers. Viomics Inc. was founded in 2012 and is based in Phoenix, Arizona. As of March 3, 2020, Viomics Inc. operates as a subsidiary of Exact Sciences Corporation.
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.